Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of RA patients in the world, and disease management is broadly based on three types of treatments—cDMARDs (e.g., methotrexate, leflunomide), biological DMARDs (TNF-α inhibitors, anti-CD20 MAbs, IL-6 inhibitors, and selective costimulation inhibitors), and JAK inhibitors. TNF-α inhibitors are the most widely prescribed targeted therapies for RA patients refractory to conventional DMARDs, and other biologics and JAK inhibitors largely compete for use in TNF-α-inhibitor-refractory-patient segment. The approval of cost-effective biosimilars and the incorporation of several therapies into China’s National Reimbursement Drug List (NRDL) has improved patient access to premium-priced therapies. Based on the improved patient access and the expected launch of additional targeted therapies during the forecast period, we believe that China’s RA therapy market is set for a robust growth.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 rheumatologists
Diagnosed prevalence of rheumatoid arthritis (RA) in urban versus rural China; clinically relevant and market-relevant drug-treatable populations
10-year, annualized, drug-level sales and patient share of key RA therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions
Phase III/PR: 8 drugs; Phase II: 6 drugs; coverage of select preclinical and Phase I products